Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Down 46.7% in March

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 255,400 shares, a drop of 46.7% from the February 28th total of 479,400 shares. Currently, 1.8% of the company’s stock are short sold. Based on an average daily trading volume, of 3,140,000 shares, the short-interest ratio is currently 0.1 days.

Aethlon Medical Trading Down 8.6 %

Shares of AEMD opened at $0.37 on Friday. The company’s 50 day simple moving average is $0.56 and its 200-day simple moving average is $0.50. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $1.79. The firm has a market cap of $5.30 million, a PE ratio of -0.23 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.09. As a group, equities research analysts forecast that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Aethlon Medical in a research report on Monday, March 10th. StockNews.com began coverage on Aethlon Medical in a report on Friday. They issued a “sell” rating for the company.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of AEMD. Allegiance Financial Group Advisory Services LLC purchased a new position in Aethlon Medical during the 4th quarter worth $26,000. Renaissance Technologies LLC purchased a new stake in shares of Aethlon Medical in the fourth quarter valued at about $25,000. Boothbay Fund Management LLC acquired a new position in shares of Aethlon Medical during the fourth quarter worth about $186,000. Sassicaia Capital Advisers LLC purchased a new position in Aethlon Medical during the fourth quarter worth about $31,000. Finally, Virtu Financial LLC acquired a new stake in Aethlon Medical in the fourth quarter valued at about $81,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.